Evidence map›Paper›PMID 42034806›Full record

ArticleScientific reports2026

XGBoost-based model for predicting five-year survival in gastric cancer using clinical indicators.

Yujiao Zhang, Xuemeng Zhou, Peixian Li, Chunfeng Li, Lixia Ke

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yujiao Zhang *Department of Oncology, Beidahuang Industry Group General Hospital, Harbin, China.
Xuemeng Zhou *Department of Oncology, Beidahuang Industry Group General Hospital, Harbin, China.
Peixian LiDepartment of Oncology, Beidahuang Industry Group General Hospital, Harbin, China.
Chunfeng LiDepartment of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin, China. lichunfeng007@hrbmu.edu.cn.
Lixia KeDepartment of Oncology, Beidahuang Industry Group General Hospital, Harbin, China. lixiake@stu.ahu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate diagnosis and prognostic assessment of gastric cancer are critical for improving patient outcomes. The application of advanced machine learning methods, particularly the XGBoost algorithm, offers a promising approach for enhancing prognostic evaluations. In this study, data from 2,270 patients with gastric cancer were analysed to develop a predictive model for prognosis using the XGBoost algorithm and 20 key clinical features. Comprehensive data collection, preprocessing, and feature selection were conducted to ensure robust model construction and validation. The model demonstrated strong predictive performance in the test cohort, achieving an area under the curve (AUC) of 0.855, and it effectively differentiated patients at high-risk from those at low-risk. Feature importance analysis revealed that pTNM stage and CA125 level were the most influential prognostic factors. This study successfully implemented a machine learning-based model integrating the XGBoost algorithm and critical clinical indicators to predict the five-year survival rate of patients with gastric cancer. The findings highlight the potential of such approaches in supporting personalised treatment strategies and advancing cancer prognosis assessment methodologies.

Indexed as

Stomach NeoplasmsAgedAlgorithmsBoosting Machine Learning AlgorithmsFemaleHumansMachine LearningMaleMiddle AgedPrediction AlgorithmsPredictive Learning ModelsPrognosisSurvival Rateclinical indicatorsgastric cancermachine learningmodelprognosis

Identifiers

PMID42034806
PMCPMC13284183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.